267 related articles for article (PubMed ID: 24417755)
21. Vascular endothelial growth factor and interleukin-6 are correlated with serous retinal detachment in central retinal vein occlusion.
Noma H; Funatsu H; Mimura T
Curr Eye Res; 2012 Jan; 37(1):62-7. PubMed ID: 21978265
[TBL] [Abstract][Full Text] [Related]
22. Predictors of anti-VEGF efficacy in chronic central serous chorioretinopathy based on intraocular cytokine levels and pigment epithelium detachment subtypes.
Mao J; Zhang C; Zhang S; Liu C; Chen N; Tao J; She X; Zheng Z; Lv Z; Shen L
Acta Ophthalmol; 2022 Nov; 100(7):e1385-e1394. PubMed ID: 35122421
[TBL] [Abstract][Full Text] [Related]
23. TWELVE-MONTH EFFICACY OF INTRAVITREAL BEVACIZUMAB INJECTION FOR CHRONIC, ATYPICAL, OR RECURRENT CENTRAL SEROUS CHORIORETINOPATHY.
Chung YR; Kim JW; Song JH; Park A; Kim MH
Retina; 2019 Jan; 39(1):134-142. PubMed ID: 29077604
[TBL] [Abstract][Full Text] [Related]
24. Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment.
Kaneda S; Miyazaki D; Sasaki S; Yakura K; Terasaka Y; Miyake K; Ikeda Y; Funakoshi T; Baba T; Yamasaki A; Inoue Y
Invest Ophthalmol Vis Sci; 2011 May; 52(6):2982-8. PubMed ID: 21273540
[TBL] [Abstract][Full Text] [Related]
25. Intravitreal bevacizumab injection for central serous chorioretinopathy.
Nowroozzadeh MH
Retina; 2010 Sep; 30(8):1322-3; author reply 1323. PubMed ID: 20827148
[No Abstract] [Full Text] [Related]
26. Intravitreal bevacizumab injection for central serous chorioretinopathy.
Chhablani JK; Narayanan R
Retina; 2010 Sep; 30(8):1323-24; author reply 1324. PubMed ID: 20661171
[No Abstract] [Full Text] [Related]
27. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study.
dell'Omo R; Cassetta M; dell'Omo E; di Salvatore A; Hughes JM; Aceto F; Porcellini A; Costagliola C
Am J Ophthalmol; 2012 Jan; 153(1):155-61.e2. PubMed ID: 21861975
[TBL] [Abstract][Full Text] [Related]
28. Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease.
Bae JH; Lee SC
Retina; 2012 Jul; 32(7):1395-402. PubMed ID: 22012204
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy.
Lee JY; Chae JB; Yang SJ; Kim JG; Yoon YH
Acta Ophthalmol; 2011 May; 89(3):e293-4. PubMed ID: 20346078
[No Abstract] [Full Text] [Related]
30. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect.
Seong HK; Bae JH; Kim ES; Han JR; Nam WH; Kim HK
Ophthalmologica; 2009; 223(5):343-7. PubMed ID: 19521133
[TBL] [Abstract][Full Text] [Related]
31. Altered plasma cytokine levels in acute and chronic central serous chorioretinopathy.
Karska-Basta I; Pociej-Marciak W; Chrząszcz M; Kubicka-Trząska A; Romanowska-Dixon B; Sanak M
Acta Ophthalmol; 2021 Mar; 99(2):e222-e231. PubMed ID: 32701204
[TBL] [Abstract][Full Text] [Related]
32. Analysis of Cytokine Levels Based on Optical Coherence Tomography Findings in Acute and Chronic Central Serous Chorioretinopathy.
Zhang C; Mao J; Zhang S; Zheng Z; Zhang Z; Xiang Z; Chen Y; Shen L
Curr Eye Res; 2023 Dec; 48(12):1153-1159. PubMed ID: 37615383
[No Abstract] [Full Text] [Related]
33. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy.
Lim JW; Ryu SJ; Shin MC
Korean J Ophthalmol; 2010 Jun; 24(3):155-8. PubMed ID: 20532141
[TBL] [Abstract][Full Text] [Related]
34. [Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection].
Gregori-Gisbert I; Aguirre-Balsalobre F; García-Sánchez J; León-Salvatierra G; Mengual-Verdú E; Hueso-Abancéns JR
Arch Soc Esp Oftalmol; 2011 Dec; 86(12):407-11. PubMed ID: 22117740
[TBL] [Abstract][Full Text] [Related]
35. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration.
Fauser S; Schwabecker V; Muether PS
Am J Ophthalmol; 2014 Sep; 158(3):532-6. PubMed ID: 24879948
[TBL] [Abstract][Full Text] [Related]
36. Effect of intravitreal triamcinolone in diabetic macular edema unresponsive to intravitreal bevacizumab.
Jeon S; Lee WK
Retina; 2014 Aug; 34(8):1606-11. PubMed ID: 24553409
[TBL] [Abstract][Full Text] [Related]
37. Success of ranibizumab in central serous chorioretinopathy resistant to bevacizumab.
Altun A; Kurna SA; Olcaysu OO; Sengor T; Aki SF; Atakan TG
J Ocul Pharmacol Ther; 2014 Dec; 30(10):842-6. PubMed ID: 25216333
[TBL] [Abstract][Full Text] [Related]
38. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
39. Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab.
Zhou M; Chen S; Wang W; Huang W; Cheng B; Ding X; Zhang X
Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):3874-9. PubMed ID: 23674760
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
Chan WM; Lai TY; Liu DT; Lam DS
Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
